Previous 10 | Next 10 |
Twist Bioscience ( TWST +5.4% ) launches Twist Respiratory Virus Research Panel , next-generation sequencing (NGS) for detection of a range of respiratory diseases, designed from reference sequences for 29 common human respiratory viruses. More news on: Twist Bioscience Corporati...
-- Panel Includes Adenoviruses, Coronaviruses, Influenzas, Rhinoviruses and More -- Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of th...
Twist Bioscience ( TWST -3.3% ) has added four new synthetic SARS-CoV-2 controls to its offering that include new variants of the coronavirus. More news on: Twist Bioscience Corporation, Healthcare stocks news, Read more ...
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the addition of four new synthetic SARS-CoV-2 RNA Controls for the development, verification, and ongoing validat...
Synthetic DNA maker Twist Bioscience ( TWST +1.7% ) will collaborate with privately held Serimmune to identify and evaluate therapeutic antibody candidates for the treatment of COVID-19. More news on: Twist Bioscience Corporation, Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO , Calif. and GOLETA, Calif. , June 9, 2020 /PRNewswire/ -- Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Serimmune Inc., a lea...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the closing of its underwritten public offering of 3,484,848 shares of its common stock at a public offering pric...
Twist Bioscience (NASDAQ: TWST ) has priced its public offering of 3,030,303 common shares at $33.00/share, for gross proceeds of ~$100M. More news on: Twist Bioscience Corporation, Healthcare stocks news, , Read more ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an underwritten public offering of 3,030,303 shares of its common stock at a price to the public o...
Privately held Proteona announces that Twist Bioscience ( TWST +0.4% ) has joined an international alliance led by Proteona aimed at developing neutralizing antibody therapies against COVID-19 for vulnerable immunocompromised patients. More news on: Twist Bioscience Corporation, Heal...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...